Forte Biosciences Shares Are Soaring Today: What's Going On?
Forte Biosciences Shares Are Soaring Today: What's Going On?
The private placement involved institutional investors including OrbiMed, Janus Henderson Investors and Tybourne Capital Management. TD Cowen served as the lead placement agent, with Guggenheim Securities providing advisory services.Forte Biosciences Inc. (NASDAQ:FBRX) shares are trading higher Wednesday. The company announced a $53 million private placement to fund the development of its autoimmune-focused drug candidate, FB102. Here's what you need to know.
Forte Biosciences股票（納斯達克：FBRX）週三交易上漲。該公司宣佈了一項5300萬美元的定向增發，用於發展其自身免疫藥物候選品FB102。以下是您需要了解的信息。
What To Know: Forte, a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced an oversubscribed $53 million equity financing to support clinical trials of FB102, including ongoing research in celiac disease with topline results expected in the second quarter of 2025.
需要了解的內容：Forte是一家專注於自身免疫和自身免疫相關疾病的臨床階段生物製藥公司，宣佈了一個超額認購的5300萬美元股權融資，以支持FB102的臨床試驗，包括在2025年第二季度預計獲得拓展結果的腹瀉疾病的持續研究。
Forte said it also plans to expand FB102 trials to other autoimmune indications within the next year.
Forte表示還計劃在未來一年內將FB102試驗擴展到其他自身免疫指標。
The private placement involved institutional investors including OrbiMed, Janus Henderson Investors and Tybourne Capital Management. TD Cowen served as the lead placement agent, with Guggenheim Securities providing advisory services.
這項定向增發涉及機構投資者，包括奧比美、雅諾斯·亨德森投資者和泰伯資本管理。TD Cowen擔任主要放置代理，古根海姆證券提供諮詢服務。
"This financing by high quality institutional investors is transformative for Forte and highlights the meaningful potential for FB102. As a result of the financing, Forte is well capitalized to continue advancing FB102 across autoimmune indications," said Paul Wagner, chairman and CEO of Forte Biosciences.
「這些高質量機構投資者的融資對Forte具有變革意義，並突顯了FB102的重要潛力。由於融資，Forte有足夠的資本繼續推動跨越自身免疫指標的FB102。」Forte Biosciences的董事長兼首席執行官保羅·瓦格納表示。
It's worth noting that there have been several trading halts in Forte's stock on Wednesday as shares surged as much as 171%. Some of the trading action appears to be retail-driven. The stock was among the top trending names on Stocktwits on Wednesday.
值得注意的是，週三Forte的股票曾出現數次交易暫停，股價一度飆升了高達171%。部分交易活動似乎受零售投資者推動。該股票是週三Stocktwits上持續關注的熱門股票之一。
13.51% of Forte's float is currently sold short, according to data from Benzinga Pro. Forte is also considered a low-float stock with just 1.37 million shares available for public trading. The company also had a market cap of less than $9 million as of Tuesday's close. Low-float, micro-cap stocks can be extremely volatile, which may help explain some of Wednesday's outsized move.
根據Benzinga Pro的數據，Forte流通股中有13.51%目前被賣空。Forte也被視爲一個流通股較少的股票，公開交易的股份僅爲137萬。截至上週二收盤，該公司市值不到900萬美元。流通股較少、微小市值的股票可能極具波動性，這可能有助於解釋週三的異常走勢。
Forte will host an R&D Day on Dec. 3 to provide additional updates on its clinical programs and development strategy.
Forte將於12月3日舉辦研發日，以提供關於其臨床項目和發展策略的進一步更新。
"As we have previously indicated, the healthy volunteer study has completed and a celiac disease trial is underway with a topline readout projected in the second quarter of 2025. We expect to advance FB102 into additional indications over the next 12 months. 2025 could be an exciting year of clinical milestones for FB102," Wagner said.
正如我們先前所表明的，健康志願者研究已經完成，並且一項腹瀉病試驗正在進行中，預計在2025年第二季度進行最終讀數。我們希望在接下來的12個月內將 FB102 推進到其他適應症。瓦格納表示："2025年可能是 FB102 在臨床里程碑方面充滿期待的一年。"
FBRX Price Action: Forte Biosciences shares were up 120.6% at 13.07 at the time of publication, according to Benzinga Pro.
FBRX 價格走勢：forte biosciences 股票在出版時上漲了120.6%，報13.07美元，據《財經新聞專業版》報道。
- Target Margins And Inventory Issues Raise Analyst Caution After Weak Q3 Performance
- 目標利潤率和庫存問題導致第三季度表現疲弱後分析師謹慎。
Image via Shutterstock.
圖片由shutterstock提供。
譯文內容由第三人軟體翻譯。
